Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Wuhan Bio-Raid Biotech Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is distributed across 1 distinct examiner and 1 distinct art unit. This indicates a singular focus for the company's current patent prosecution efforts, with all pending resources dedicated to one specific application. Such a focused profile allows for a very direct prosecution strategy but limits the company's current exposure to different examination styles within the Biotechnology & Pharmaceuticals sector.
The busiest examiner identified in the data is ALFANO, ALAN, who is responsible for 1 busiest examiner pending office action. Because this examiner is the only one currently assigned to a pending matter for the company, the prosecution strategy must be tailored to this specific relationship. Practitioners should monitor the patterns of ALFANO, ALAN to anticipate the next steps for Wuhan Bio-Raid Biotech Co. Ltd. Success in this matter will depend on addressing the specific concerns raised by this examiner in the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALFANO, ALAN | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557875 | CD99-targeting chimeric antigen receptor and application thereof | ALFANO, ALAN | 1641 | §112 | Non-Final OA | — | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWuhan Bio-Raid Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alan Alfano has the most, with 1 of Wuhan Bio-Raid Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
